Dose Modifications | IMDELLTRA™ (tarlatamab-dlle)

To manage AEs, including CRS and ICANS, dose modifications or discontinuation may be required¹

Dose reductions are not recommended with IMDELLTRA^™¹

IMDELLTRA^™ was permanently discontinued due to adverse reactions in 7% of patients.^1,*

AE	Severity	Dose Modifications	Management Strategies
CRS^1,†	Grade 1 Symptoms require symptomatic treatment only (eg, fever ≥ 100.4°F without hypotension or hypoxia)	Withhold IMDELLTRA^™ until event resolves, then resume IMDELLTRA^™ at the next scheduled dose	Administer symptomatic treatment (eg, acetaminophen) for fever
	Grade 2 Symptoms require and respond to moderate intervention Fever ≥ 100.4°F Hypotension responsive to fluids not requiring vasopressors, and/or Hypoxia requiring low-flow nasal cannula or blow-by	Withhold IMDELLTRA^™ until event resolves, then resume IMDELLTRA^™ at the next scheduled dose	Recommend hospitalization for a minimum of 24 hours with cardiac telemetry and pulse oximetry Administer symptomatic treatment (eg, acetaminophen) for fever Administer supplemental oxygen and intravenous fluids (IVF) when indicated Consider dexamethasone^‡ (or equivalent) 8 mg IV Consider tocilizumab (or equivalent) When resuming treatment at the next planned dose, monitor patients from the start of the IMDELLTRA^™ infusion for 22 to 24 hours in an appropriate healthcare setting
	Grade 3 Severe symptoms defined as temperature ≥ 100.4°F with: Hemodynamic instability requiring a vasopressor (with or without vasopressin) or Worsening hypoxia or respiratory distress requiring high flow nasal cannula (> 6 L/min oxygen) or face mask	Withhold IMDELLTRA^™ until the event resolves, then resume IMDELLTRA^™ at the next scheduled dose For recurrent Grade 3 events, permanently discontinue IMDELLTRA^™	In addition to Grade 2 treatment: Recommend intensive monitoring (eg, ICU care) Administer dexamethasone^‡ (or equivalent) 8 mg IV every 8 hours up to 3 doses Vasopressor support as needed High-flow oxygen support as needed Recommend tocilizumab (or equivalent) Prior to the next dose, administer concomitant medications as recommended for Cycle 1 When resuming treatment at the next planned dose, monitor patients from the start of the IMDELLTRA^™ infusion for 22 to 24 hours in an appropriate healthcare setting
	Grade 4 Life-threatening symptoms defined as temperature ≥ 100.4°F with: Hemodynamic instability requiring multiple vasopressors (excluding vasopressin) Worsening hypoxia or respiratory distress despite oxygen administration requiring positive pressure	Permanently discontinue IMDELLTRA^™	ICU care Per Grade 3 treatment Recommend tocilizumab (or equivalent)
Neurologic toxicity, including ICANS^1,§	ICANS Grade 1 ICE score 7–9^** with no depressed level of consciousness	Withhold IMDELLTRA^™ until ICANS resolves, then resume IMDELLTRA^™ at the next scheduled dose	Supportive care
	ICANS Grade 2 ICE score 3–6^** and/or Mild somnolence awaking to voice	Withhold IMDELLTRA^™ until ICANS resolves, then resume IMDELLTRA^™ at the next scheduled dose	Supportive care Dexamethasone^‡ (or equivalent) 10 mg IV. Can repeat every 6 hours or methylprednisolone 1 mg/kg IV every 12 hours if symptoms worsen Monitor neurologic symptoms and consider consultation with neurologist and other specialists for further evaluation and management Monitor patients for 22 to 24 hours following the next dose of IMDELLTRA^™
	ICANS Grade 3 ICE score 0–2^** and/or Depressed level of consciousness awakening only to tactile stimulus and/or Any clinical seizure, focal or generalized, that resolves rapidly or nonconvulsive seizures on EEG that resolve with intervention and/or Focal or local edema on neuroimaging	Withhold IMDELLTRA^™ until ICANS resolves, then resume IMDELLTRA^™ at the next scheduled dose If there is no improvement to Grade ≤ 1 within 7 days, or Grade 3 toxicity reoccurs within 7 days of reinitiation, permanently discontinue IMDELLTRA^™ For recurrent Grade 3 events, permanently discontinue IMDELLTRA^™	Recommend intensive monitoring (eg, ICU care) Consider mechanical ventilation for airway protection Dexamethasone^‡ (or equivalent) 10 mg IV every 6 hours or methylprednisolone 1 mg/kg IV every 12 hours Consider repeat neuroimaging (CT or MRI) every 2–3 days if patient has persistent Grade ≥ 3 neurotoxicity Monitor patients for 22 to 24 hours following the next dose of IMDELLTRA^™
	ICANS Grade 4 ICE score 0^** (patient is unarousable and unable to perform ICE) and/or Stupor or coma and/or Life-threatening prolonged seizure (> 5 minutes) or repetitive clinical or electrical seizures without return to baseline in between and/or Diffuse cerebral edema on neuroimaging, decerebrate or decorticate posturing or papilledema, cranial nerve VI palsy, or Cushing’s triad	Permanently discontinue IMDELLTRA^™	ICU care Consider mechanical ventilation for airway protection High-dose corticosteroids^‡ Consider repeat neuroimaging (CT or MRI) every 2–3 days if patient has persistent Grade ≥ 3 neurotoxicity Treat convulsive status epilepticus per institutional guidelines

^* Based on 187 patients with ES-SCLC from Study DeLLphi-300 and Study DeLLphi-301 who received IMDELLTRA™ 1 mg on Cycle 1 Day 1 followed by 10 mg on Days 8 and 15 and then every 2 weeks until disease progression or intolerable toxicity.¹

^† CRS grading, dosage modifications, and management are based on American Society for Transplantation and Cellular Therapy (ASTCT) Consensus Grading (2019).¹

^‡ Taper steroids per standard-of-care guidelines.¹

^§ ICANS grading, dosage modifications, and management are based on ASTCT Consensus Grading (2019).¹

^** If patient is arousable and able to perform ICE Assessment, assess: Orientation (oriented to year, month, city, hospital = 4 points); Naming (names 3 objects, eg, point to clock, pen, button = 3 points); Following Commands (eg, “show me 2 fingers” or “close your eyes and stick out your tongue” = 1 point); Writing (ability to write a standard sentence = 1 point); and Attention (count backwards from 100 by ten = 1 point). If patient is unarousable and unable to perform ICE Assessment (Grade 4 ICANS) = 0 points.¹

ICE Assessment Tool²

Assessment	Points
Orientation: Orientation to year, month, city, hospital	4
Naming: Ability to name 3 objects (eg, point to clock, pen, button)	3
Following commands: Ability to follow simple commands (eg, “show me 2 fingers” or “close your eyes and stick out your tongue”)	1
Writing: Ability to write a standard sentence (eg, “our national bird is the bald eagle”)	1
Attention: Ability to count backwards from 100 by 10	1

Adverse Event	Severity^††	Dosage Modifications
Cytopenias¹	Grade 3 or Grade 4 neutropenia	Withhold IMDELLTRA^™ until recovery to ≤ Grade 2 Consider administration of granulocyte colony stimulating factor (G-CSF) Permanently discontinue if recovery to ≤ Grade 2 does not occur within 3 weeks
	Recurrent Grade 4 neutropenia	Permanently discontinue IMDELLTRA^™
	Febrile neutropenia	Withhold IMDELLTRA^™ until neutropenia recovers to ≤ Grade 2 and fever resolves
	Hemoglobin < 8 g/dL	Withhold IMDELLTRA^™ until hemoglobin is ≥ 8 g/dL
	Grade 3 or Grade 4 decreased platelet count	Withhold IMDELLTRA^™ until platelet count is ≤ Grade 2 and no evidence of bleeding Permanently discontinue if recovery to ≤ Grade 2 does not occur within 3 weeks
	Recurrent Grade 4 decreased platelet count	Permanently discontinue IMDELLTRA^™
Infections¹	All Grades	Withhold IMDELLTRA^™ in the step-up phase in patients until infection resolves
	Grade 3	Withhold IMDELLTRA™ during the treatment phase until infection improves to ≤ Grade 1
	Grade 4	Consider permanent discontinuation of IMDELLTRA^™
Hepatotoxicity¹	Grade 3 increased ALT or AST or bilirubin	Withhold IMDELLTRA^™ until adverse events improve to ≤ Grade 1
	Grade 4 increased ALT or AST or bilirubin	Permanently discontinue IMDELLTRA^™ If IMDELLTRA^™ is not permanently discontinued, withhold subsequent treatment doses of IMDELLTRA^™ until adverse events improve to ≤ Grade 1
	Recurrent Grade 4	Permanently discontinue IMDELLTRA^™
	AST or ALT > 3 × ULN with total bilirubin > 2 × ULN in the absence of alternative causes	Permanently discontinue IMDELLTRA^™
Other adverse reactions¹	Grade 3 or 4	Withhold IMDELLTRA^™ until recovery to ≤ Grade 1 or baseline Consider permanently discontinuing if adverse reaction does not resolve within 28 days Consider permanent discontinuation for Grade 4 events

^†† Severity based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.¹

Restarting IMDELLTRA^™ after dosage delay

Last Dose Administered	Time Since the Last Dose Administered	Action^‡‡
1 mg on Cycle 1 Day 1¹	2 weeks or less (≤ 14 days)	Administer IMDELLTRA^™ 10 mg, then resume with the planned dosage schedule
1 mg on Cycle 1 Day 1¹	Greater than 2 weeks (> 14 days)	Administer IMDELLTRA^™ step-up dose 1 mg. If tolerated, increase to 10 mg 1 week later, then resume with the planned dosage schedule
10 mg on Cycle 1 Day 8¹	3 weeks or less (≤ 21 days)	Administer IMDELLTRA^™ 10 mg, then resume with the planned dosage schedule
10 mg on Cycle 1 Day 8¹	Greater than 3 weeks (> 21 days)	Administer IMDELLTRA^™ step-up dose 1 mg. If tolerated, increase to 10 mg 1 week later, then resume with the planned dosage schedule
10 mg on Cycle 1 Day 15 and subsequent Cycles Q2W thereafter¹	4 weeks or less (≤ 28 days)	Administer IMDELLTRA^™ 10 mg, then resume with the planned dosage schedule
	Greater than 4 weeks (> 28 days)	Administer IMDELLTRA^™ step-up dose 1 mg. If tolerated, increase to 10 mg 1 week later, then resume with the planned dosage schedule

^‡‡ Administer recommended concomitant medications before and after Cycle 1 IMDELLTRA^™ infusions and monitor patients accordingly.¹

RESOURCES & SUPPORT

AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRS, cytokine release syndrome; CT, computed tomography; EEG, electroencephalogram; ES-SCLC, extensive-stage small cell lung cancer; ICANS, immune effector cell–associated neurotoxicity syndrome; ICE, immune effector cell–associated encephalopathy; ICU, intensive care unit; IV, intravenous; MRI, magnetic resonance imaging; Q2W, every 2 weeks; ULN, upper limit of normal.

IMPORTANT SAFETY INFORMATION

WARNING: CYTOKINE RELEASE SYNDROME AND NEUROLOGIC TOXICITY including IMMUNE EFFECTOR CELL‐ASSOCIATED NEUROTOXICITY SYNDROME

Cytokine release syndrome (CRS), including serious or life-threatening reactions, can occur in patients receiving IMDELLTRA™. Initiate treatment with IMDELLTRA™ using the step-up dosing schedule to reduce the incidence and severity of CRS. Withhold IMDELLTRA™ until CRS resolves or permanently discontinue based on severity.
Neurologic toxicity, including immune effector cell‐associated neurotoxicity syndrome (ICANS), including serious or life-threatening reactions, can occur in patients receiving IMDELLTRA™. Monitor patients for signs and symptoms of neurologic toxicity, including ICANS, during treatment and treat promptly. Withhold IMDELLTRA™ until ICANS resolves or permanently discontinue based on severity.

WARNINGS AND PRECAUTIONS

Cytokine Release Syndrome (CRS): IMDELLTRA™ can cause CRS including serious or life-threatening reactions. In the pooled safety population, CRS occurred in 55% of patients who received IMDELLTRA™, including 34% Grade 1, 19% Grade 2, 1.1% Grade 3 and 0.5% Grade 4. Recurrent CRS occurred in 24% of patients, including 18% Grade 1 and 6% Grade 2.

Most events (43%) of CRS occurred after the first dose, with 29% of patients experiencing any grade CRS after the second dose and 9% of patients experiencing CRS following the third dose or later. Following the Day 1, Day 8, and Day 15 infusions, 16%, 4.3% and 2.1% of patients experienced ≥ Grade 2 CRS, respectively. The median time to onset of all grade CRS from most recent dose of IMDELLTRA™ was 13.5 hours (range: 1 to 268 hours). The median time to onset of ≥ Grade 2 CRS from most recent dose of IMDELLTRA™ was 14.6 hours (range: 2 to 566 hours).

Clinical signs and symptoms of CRS included pyrexia, hypotension, fatigue, tachycardia, headache, hypoxia, nausea, and vomiting. Potentially life-threatening complications of CRS may include cardiac dysfunction, acute respiratory distress syndrome, neurologic toxicity, renal and/or hepatic failure, and disseminated intravascular coagulation (DIC).

Administer IMDELLTRA™ following the recommended step-up dosing and administer concomitant medications before and after Cycle 1 IMDELLTRA™ infusions as described in Table 3 of the Prescribing Information (PI) to reduce the risk of CRS. Administer IMDELLTRA™ in an appropriate health care facility equipped to monitor and manage CRS. Ensure patients are well hydrated prior to administration of IMDELLTRA™.

Closely monitor patients for signs and symptoms of CRS during treatment with IMDELLTRA™. At the first sign of CRS, immediately discontinue IMDELLTRA™ infusion, evaluate the patient for hospitalization and institute supportive care based on severity. Withhold or permanently discontinue IMDELLTRA™ based on severity. Counsel patients to seek medical attention should signs or symptoms of CRS occur.
Neurologic Toxicity, Including ICANS: IMDELLTRA™ can cause serious or life-threatening neurologic toxicity, including ICANS. In the pooled safety population, neurologic toxicity, including ICANS, occurred in 47% of patients who received IMDELLTRA™, including 10% Grade 3. The most frequent neurologic toxicities were headache (14%), peripheral neuropathy (7%), dizziness (7%), insomnia (6%), muscular weakness (3.7%), delirium (2.1%), syncope (1.6%), and neurotoxicity (1.1%).

ICANS occurred in 9% of IMDELLTRA™-treated patients. Recurrent ICANS occurred in 1.6% of patients. Most patients experienced ICANS following Cycle 2 Day 1 (24%). Following Day 1, Day 8, and Day 15 infusions, 0.5%, 0.5% and 3.7% of patients experienced ≥ Grade 2 ICANS, respectively. The median time to onset of ICANS from the first dose of IMDELLTRA™ was 29.5 days (range: 1 to 154 days). ICANS can occur several weeks following administration of IMDELLTRA™. The median time to resolution of ICANS was 33 days (range: 1 to 93 days).

The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS. Clinical signs and symptoms of ICANS may include but are not limited to confusional state, depressed level of consciousness, disorientation, somnolence, lethargy, and bradyphrenia.

Patients receiving IMDELLTRA™ are at risk of neurologic adverse reactions and ICANS resulting in depressed level of consciousness. Advise patients to refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery, in the event of any neurologic symptoms until they resolve.

Closely monitor patients for signs and symptoms of neurologic toxicity and ICANS during treatment. At the first sign of ICANS, immediately evaluate the patient and provide supportive therapy based on severity. Withhold IMDELLTRA™ or permanently discontinue based on severity.
Cytopenias: IMDELLTRA™ can cause cytopenias including neutropenia, thrombocytopenia, and anemia. In the pooled safety population, decreased neutrophils occurred in 12% including 6% Grade 3 or 4 of IMDELLTRA™-treated patients. The median time to onset for Grade 3 or 4 neutropenia was 29.5 days (range: 2 to 213). Decreased platelets occurred in 33% including 3.2% Grade 3 or 4. The median time to onset for Grade 3 or 4 decreased platelets was 50 days (range: 3 to 420). Decreased hemoglobin occurred in 58% including 5% Grade 3 or 4. Febrile neutropenia occurred in 0.5% of patients treated with IMDELLTRA™.

Monitor patients for signs and symptoms of cytopenias. Perform complete blood counts prior to treatment with IMDELLTRA™, before each dose, and as clinically indicated. Based on the severity of cytopenias, temporarily withhold, or permanently discontinue IMDELLTRA™.
Infections: IMDELLTRA™ can cause serious infections, including life-threatening and fatal infections.

In the pooled safety population, infections, including opportunistic infections, occurred in 41% of patients who received IMDELLTRA™. Grade 3 or 4 infections occurred in 13% of patients. The most frequent infections were COVID-19 (9%, majority during the COVID-19 pandemic), urinary tract infection (10%), pneumonia (9%), respiratory tract infection (3.2%), and candida infection (3.2%).

Monitor patients for signs and symptoms of infection prior to and during treatment with IMDELLTRA™ and treat as clinically indicated. Withhold or permanently discontinue IMDELLTRA™ based on severity.
Hepatotoxicity: IMDELLTRA™ can cause hepatotoxicity. In the pooled safety population, elevated ALT occurred in 42%, with Grade 3 or 4 ALT elevation occurring in 2.1%. Elevated AST occurred in 44% of patients, with Grade 3 or 4 AST elevation occurring in 3.2%. Elevated bilirubin occurred in 15% of patients; Grade 3 or 4 total bilirubin elevations occurred in 1.6% of patients. Liver enzyme elevation can occur with or without concurrent CRS. Monitor liver enzymes and bilirubin prior to treatment with IMDELLTRA™, before each dose, and as clinically indicated. Withhold IMDELLTRA™ or permanently discontinue based on severity.
Hypersensitivity: IMDELLTRA™ can cause severe hypersensitivity reactions. Clinical signs and symptoms of hypersensitivity may include, but are not limited to, rash and bronchospasm. Monitor patients for signs and symptoms of hypersensitivity during treatment with IMDELLTRA™ and manage as clinically indicated. Withhold or consider permanent discontinuation of IMDELLTRA™ based on severity.
Embryo-Fetal Toxicity: Based on its mechanism of action, IMDELLTRA™ may cause fetal harm when administered to a pregnant woman. Advise patients of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with IMDELLTRA™ and for 2 months after the last dose.

ADVERSE REACTIONS

The most common (> 20%) adverse reactions were CRS (55%), fatigue (51%), pyrexia (36%), dysgeusia (36%), decreased appetite (34%), musculoskeletal pain (30%), constipation (30%), anemia (27%), and nausea (22%). The most common (≥ 2%) Grade 3 or 4 laboratory abnormalities were decreased lymphocytes (57%), decreased sodium (16%), increased uric acid (10%), decreased total neutrophils (6%), decreased hemoglobin (5%), increased activated partial thromboplastin time (5%), decreased potassium (5%), increased aspartate aminotransferase (3.2%), decreased white blood cells (3.8%), decreased platelets (3.2%), and increased alanine aminotransferase (2.1%).
Serious adverse reactions occurred in 58% of patients. Serious adverse reactions in > 3% of patients included CRS (24%), pneumonia (6%), pyrexia (3.7%), and hyponatremia (3.6%). Fatal adverse reactions occurred in 2.7% of patients including pneumonia (0.5%), aspiration (0.5%), pulmonary embolism (0.5%), respiratory acidosis (0.5%), and respiratory failure (0.5%).

DOSAGE AND ADMINISTRATION: Important Dosing Information

Administer IMDELLTRA™ as an intravenous infusion over one hour.
Administer IMDELLTRA™ according to the step-up dosing schedule in the IMDELLTRA™ PI (Table 1) to reduce the incidence and severity of CRS.
For Cycle 1, administer recommended concomitant medications before and after Cycle 1 IMDELLTRA™ infusions to reduce the risk of CRS reactions as described in the PI (Table 3).
IMDELLTRA™ should only be administered by a qualified healthcare professional with appropriate medical support to manage severe reactions such as CRS and neurologic toxicity including ICANS.
Due to the risk of CRS and neurologic toxicity, including ICANS, monitor patients from the start of the IMDELLTRA™ infusion for 22 to 24 hours on Cycle 1 Day 1 and Cycle 1 Day 8 in an appropriate healthcare setting.
Recommend that patients remain within 1 hour of an appropriate healthcare setting for a total of 48 hours from start of the infusion with IMDELLTRA™ following Cycle 1 Day 1 and Cycle 1 Day 8 doses, accompanied by a caregiver.
Prior to administration of IMDELLTRA™, evaluate complete blood count, liver enzymes, and bilirubin before each dose, and as clinically indicated.
Ensure patients are well hydrated prior to administration of IMDELLTRA™.

INDICATION

IMDELLTRA™ (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Please see IMDELLTRA^™ full Prescribing Information, including BOXED WARNINGS.

References: 1. IMDELLTRA^™ (tarlatamab-dlle) prescribing information, Amgen. 2. Ahn M-J, et al. N Engl J Med. 2023;389:2063-2075. 3. Ahn M-J, et al. N Engl J Med. 2023;389(suppl):2063-2075. 4. Shimabukuro-Vornhagen A, et al. J Immunother Cancer. 2018;6:56. 5. Lee DW, et al. Biol Blood Marrow Transplant. 2019;25:625-638.

References: 1. IMDELLTRA^™ (tarlatamab-dlle) prescribing information, Amgen. 2. Lee DW, et al. Biol Blood Marrow Transplant. 2019;25:625-638.

References: 1. IMDELLTRA^™ (tarlatamab-dlle) prescribing information, Amgen. 2. Ahn M-J, et al. N Engl J Med. 2023;389:2063-2075. 3. Ahn M-J, et al. N Engl J Med. 2023;389(suppl):2063-2075.

References: 1. Rudin CM, et al. Nat Rev Dis Primers. 2021;7:3. 2. Sabari JK, et al. Nat Rev Clin Oncol. 2017;14:549-561. 3. National Cancer Institute. www.cancer.gov. Accessed March 22, 2024. 4. IMDELLTRA™ (tarlatamab-dlle) prescribing information, Amgen. 5. Leonetti A, et al. Cell Oncol (Dordr). 2019;42:261-273. 6. Rojo F, et al. Lung Cancer. 2020;147:237-243. 7. Ahn M-J, et al. N Engl J Med. 2023;389:2063-2075.

References: 1. IMDELLTRA^™ (tarlatamab-dlle) prescribing information, Amgen. 2. Ahn M-J, et al. N Engl J Med. 2023;389:2063-2075. 3. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05060016. Accessed October 30, 2023.

IMPORTANT SAFETY INFORMATION

WARNING: CYTOKINE RELEASE SYNDROME AND NEUROLOGIC TOXICITY including IMMUNE EFFECTOR CELL‐ASSOCIATED NEUROTOXICITY SYNDROME

Cytokine release syndrome (CRS), including serious or life-threatening reactions, can occur in patients

You are leaving IMDELLTRAhcp.com

You are leaving IMDELLTRAhcp.com

To manage AEs, including CRS and ICANS, dose modifications or discontinuation may be required1

Dose reductions are not recommended with IMDELLTRA™1

ICE Assessment Tool2

Restarting IMDELLTRA™ after dosage delay

IMPORTANT SAFETY INFORMATION

WARNING: CYTOKINE RELEASE SYNDROME AND NEUROLOGIC TOXICITY including IMMUNE EFFECTOR CELL‐ASSOCIATED NEUROTOXICITY SYNDROME

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

DOSAGE AND ADMINISTRATION: Important Dosing Information

INDICATION

IMPORTANT SAFETY INFORMATION

WARNING: CYTOKINE RELEASE SYNDROME AND NEUROLOGIC TOXICITY including IMMUNE EFFECTOR CELL‐ASSOCIATED NEUROTOXICITY SYNDROME

You are leaving
IMDELLTRAhcp.com

You are leaving
IMDELLTRAhcp.com

To manage AEs, including CRS and ICANS, dose modifications or discontinuation may be required¹

Dose reductions are not recommended with IMDELLTRA^™¹

ICE Assessment Tool²

Restarting IMDELLTRA^™ after dosage delay